Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Small Molecules Studied

HMS LINCS ID Name Alternative Names LINCS ID Structure Image PubChem CID
10232-2 Dactolisib
BEZ235; NVP-BEZ235
 LSM-4255 11977753
10133-2 Afatinib
BIBW-2992
 LSM-43226 57519523
10504-1 Chk2 inhibitor II
BML-277
 9969021
10258-1 Ibandronate
Boniva
 LSM-4279 44828485
10245-1 Cisplatin
CDDP; cis-Diaminodichloroplatinum; Cisplatinum; Lederplatin; Briplatin; Cismaplat
 LSM-4268
10503-1 Celecoxib
Celebrex; Celebra; Celecox; Onsenal; Solexa; SC-58635; YM-177
 2662
10230-2 Lestaurtinib
CEP-701
 LSM-1231 126565
10048-7 PD184352
CI-1040
 LSM-1048 6918454
10048-6 PD184352
CI-1040
 LSM-1048 6918454
10346-1 Valproic acid
Depakine
 LSM-4620 3549980
10249-1 Epirubicin
Ellence
 LSM-2078 41867
10269-1 Oxaliplatin
Eloxatin
 LSM-44941 5310940
10515-1 QNZ
EVP4593
 509554
10238-1 5-FU
Fluorouracil
 LSM-4261 3385
10110-3 FR180204
FR 180204; KIN001-230
 LSM-42790 11493598
10252-1 Gemcitabine
Gemzar
 LSM-5333 60750
10023-3 Imatinib
Gleevec; Glivec; CGP-57148B; STI-571
 LSM-1023 5291
10142-2 Trametinib
GSK-1120212; GSK1120212; GSK1120212B; JTP-74057
 LSM-1143 11707110
10146-2 Omipalisib
GSK2126458; GSK2126458A
 LSM-1147 25167777
10013-3 GSK461364
GSK461364A
 LSM-1013 15983966
10051-3 Lapatinib
GW-572016; Tykerb
 LSM-1051 208908
10014-3 GW843682X
GW843682
 LSM-1014 9826308
10278-1 Topotecan
Hycamtin
 LSM-5662 60700
10509-1 GM6001
Ilomastat; Galardin; GM-6001
 132519
10246-1 CPT-11
Irinotecan
 LSM-2167 60838